Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease

Peter A. McCullough, Anupama Vasudevan, Mohanakrishnan Sathyamoorthy, Jeffrey M. Schussler, Carlos E. Velasco, Luis R. Lopez, Caren Swift, Margarita Peterson, Jenna Bennett-Firmin, Raphael Schiffmann, Teodoro Bottiglieri

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Antiplatelet therapy with aspirin has been shown to reduce adverse outcomes in patients with coronary artery disease (CAD). Aspirin irreversibly inhibits platelet cyclooxygenase-1 and attenuates thromboxane A2 (TXA2)–mediated platelet aggregation, but there is variable suppression of cyclooxygenase-1. From a cohort of patients with stable CAD, we performed blinded, detailed chart abstraction, and measured urinary 11-dehydro-thromboxane B2 (11dhTxB2), an inactive metabolite of TxA2 from frozen samples. There were 327 men (73%) and 122 women (27%) with a mean age (±SD) of 67 ± 10 and 65 ± 10 years, respectively. A positive linear trend for age was observed among tertiles of 11dhTxB2 (p trend = 0.01). Higher proportions of women (p = 0.001), chronic obstructive pulmonary disease (p trend = 0.0003), and heart failure (p trend = 0.003) were observed in the upper tertile of 11dhTxB2. Sixty-seven patients (14.9%) died over a median follow-up of 1,149 days and 87.5% of the deaths were due to cardiovascular causes. Twenty-six nonsurvivors (38.8%) were treated with P2Y12 receptor antagonists versus 161 survivors (42.2%; p = 0.61). By stepwise Cox proportional hazards analysis, we identified that patients in the middle (hazard ratio 7.14; 95% CI 2.46 to 20.68) and upper tertiles (hazard ratio 9.91; 95% CI 3.45 to 28.50) had higher risks for mortality after adjusting for age and co-morbidities. In conclusion, urinary concentration of 11dhTxB2 was a strong independent risk factor for all-cause mortality among patients with stable CAD on aspirin therapy and may be a marker for patients with CAD who require more intensive secondary prevention measures.

Original languageEnglish (US)
Pages (from-to)972-977
Number of pages6
JournalAmerican Journal of Cardiology
Volume119
Issue number7
DOIs
StatePublished - Apr 1 2017

Fingerprint

Coronary Artery Disease
Mortality
Aspirin
Cyclooxygenase 1
Purinergic P2Y Receptor Antagonists
Thromboxane A2
Secondary Prevention
Platelet Aggregation
Chronic Obstructive Pulmonary Disease
Survivors
11-dehydro-thromboxane B2
Blood Platelets
Heart Failure
Morbidity
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

McCullough, P. A., Vasudevan, A., Sathyamoorthy, M., Schussler, J. M., Velasco, C. E., Lopez, L. R., ... Bottiglieri, T. (2017). Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease. American Journal of Cardiology, 119(7), 972-977. https://doi.org/10.1016/j.amjcard.2016.12.004

Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease. / McCullough, Peter A.; Vasudevan, Anupama; Sathyamoorthy, Mohanakrishnan; Schussler, Jeffrey M.; Velasco, Carlos E.; Lopez, Luis R.; Swift, Caren; Peterson, Margarita; Bennett-Firmin, Jenna; Schiffmann, Raphael; Bottiglieri, Teodoro.

In: American Journal of Cardiology, Vol. 119, No. 7, 01.04.2017, p. 972-977.

Research output: Contribution to journalArticle

McCullough, PA, Vasudevan, A, Sathyamoorthy, M, Schussler, JM, Velasco, CE, Lopez, LR, Swift, C, Peterson, M, Bennett-Firmin, J, Schiffmann, R & Bottiglieri, T 2017, 'Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease', American Journal of Cardiology, vol. 119, no. 7, pp. 972-977. https://doi.org/10.1016/j.amjcard.2016.12.004
McCullough PA, Vasudevan A, Sathyamoorthy M, Schussler JM, Velasco CE, Lopez LR et al. Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease. American Journal of Cardiology. 2017 Apr 1;119(7):972-977. https://doi.org/10.1016/j.amjcard.2016.12.004
McCullough, Peter A. ; Vasudevan, Anupama ; Sathyamoorthy, Mohanakrishnan ; Schussler, Jeffrey M. ; Velasco, Carlos E. ; Lopez, Luis R. ; Swift, Caren ; Peterson, Margarita ; Bennett-Firmin, Jenna ; Schiffmann, Raphael ; Bottiglieri, Teodoro. / Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease. In: American Journal of Cardiology. 2017 ; Vol. 119, No. 7. pp. 972-977.
@article{2da60b76c8214cae939ad18c16192dd3,
title = "Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease",
abstract = "Antiplatelet therapy with aspirin has been shown to reduce adverse outcomes in patients with coronary artery disease (CAD). Aspirin irreversibly inhibits platelet cyclooxygenase-1 and attenuates thromboxane A2 (TXA2)–mediated platelet aggregation, but there is variable suppression of cyclooxygenase-1. From a cohort of patients with stable CAD, we performed blinded, detailed chart abstraction, and measured urinary 11-dehydro-thromboxane B2 (11dhTxB2), an inactive metabolite of TxA2 from frozen samples. There were 327 men (73{\%}) and 122 women (27{\%}) with a mean age (±SD) of 67 ± 10 and 65 ± 10 years, respectively. A positive linear trend for age was observed among tertiles of 11dhTxB2 (p trend = 0.01). Higher proportions of women (p = 0.001), chronic obstructive pulmonary disease (p trend = 0.0003), and heart failure (p trend = 0.003) were observed in the upper tertile of 11dhTxB2. Sixty-seven patients (14.9{\%}) died over a median follow-up of 1,149 days and 87.5{\%} of the deaths were due to cardiovascular causes. Twenty-six nonsurvivors (38.8{\%}) were treated with P2Y12 receptor antagonists versus 161 survivors (42.2{\%}; p = 0.61). By stepwise Cox proportional hazards analysis, we identified that patients in the middle (hazard ratio 7.14; 95{\%} CI 2.46 to 20.68) and upper tertiles (hazard ratio 9.91; 95{\%} CI 3.45 to 28.50) had higher risks for mortality after adjusting for age and co-morbidities. In conclusion, urinary concentration of 11dhTxB2 was a strong independent risk factor for all-cause mortality among patients with stable CAD on aspirin therapy and may be a marker for patients with CAD who require more intensive secondary prevention measures.",
author = "McCullough, {Peter A.} and Anupama Vasudevan and Mohanakrishnan Sathyamoorthy and Schussler, {Jeffrey M.} and Velasco, {Carlos E.} and Lopez, {Luis R.} and Caren Swift and Margarita Peterson and Jenna Bennett-Firmin and Raphael Schiffmann and Teodoro Bottiglieri",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.amjcard.2016.12.004",
language = "English (US)",
volume = "119",
pages = "972--977",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Urinary 11-Dehydro-Thromboxane B2 and Mortality in Patients With Stable Coronary Artery Disease

AU - McCullough, Peter A.

AU - Vasudevan, Anupama

AU - Sathyamoorthy, Mohanakrishnan

AU - Schussler, Jeffrey M.

AU - Velasco, Carlos E.

AU - Lopez, Luis R.

AU - Swift, Caren

AU - Peterson, Margarita

AU - Bennett-Firmin, Jenna

AU - Schiffmann, Raphael

AU - Bottiglieri, Teodoro

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Antiplatelet therapy with aspirin has been shown to reduce adverse outcomes in patients with coronary artery disease (CAD). Aspirin irreversibly inhibits platelet cyclooxygenase-1 and attenuates thromboxane A2 (TXA2)–mediated platelet aggregation, but there is variable suppression of cyclooxygenase-1. From a cohort of patients with stable CAD, we performed blinded, detailed chart abstraction, and measured urinary 11-dehydro-thromboxane B2 (11dhTxB2), an inactive metabolite of TxA2 from frozen samples. There were 327 men (73%) and 122 women (27%) with a mean age (±SD) of 67 ± 10 and 65 ± 10 years, respectively. A positive linear trend for age was observed among tertiles of 11dhTxB2 (p trend = 0.01). Higher proportions of women (p = 0.001), chronic obstructive pulmonary disease (p trend = 0.0003), and heart failure (p trend = 0.003) were observed in the upper tertile of 11dhTxB2. Sixty-seven patients (14.9%) died over a median follow-up of 1,149 days and 87.5% of the deaths were due to cardiovascular causes. Twenty-six nonsurvivors (38.8%) were treated with P2Y12 receptor antagonists versus 161 survivors (42.2%; p = 0.61). By stepwise Cox proportional hazards analysis, we identified that patients in the middle (hazard ratio 7.14; 95% CI 2.46 to 20.68) and upper tertiles (hazard ratio 9.91; 95% CI 3.45 to 28.50) had higher risks for mortality after adjusting for age and co-morbidities. In conclusion, urinary concentration of 11dhTxB2 was a strong independent risk factor for all-cause mortality among patients with stable CAD on aspirin therapy and may be a marker for patients with CAD who require more intensive secondary prevention measures.

AB - Antiplatelet therapy with aspirin has been shown to reduce adverse outcomes in patients with coronary artery disease (CAD). Aspirin irreversibly inhibits platelet cyclooxygenase-1 and attenuates thromboxane A2 (TXA2)–mediated platelet aggregation, but there is variable suppression of cyclooxygenase-1. From a cohort of patients with stable CAD, we performed blinded, detailed chart abstraction, and measured urinary 11-dehydro-thromboxane B2 (11dhTxB2), an inactive metabolite of TxA2 from frozen samples. There were 327 men (73%) and 122 women (27%) with a mean age (±SD) of 67 ± 10 and 65 ± 10 years, respectively. A positive linear trend for age was observed among tertiles of 11dhTxB2 (p trend = 0.01). Higher proportions of women (p = 0.001), chronic obstructive pulmonary disease (p trend = 0.0003), and heart failure (p trend = 0.003) were observed in the upper tertile of 11dhTxB2. Sixty-seven patients (14.9%) died over a median follow-up of 1,149 days and 87.5% of the deaths were due to cardiovascular causes. Twenty-six nonsurvivors (38.8%) were treated with P2Y12 receptor antagonists versus 161 survivors (42.2%; p = 0.61). By stepwise Cox proportional hazards analysis, we identified that patients in the middle (hazard ratio 7.14; 95% CI 2.46 to 20.68) and upper tertiles (hazard ratio 9.91; 95% CI 3.45 to 28.50) had higher risks for mortality after adjusting for age and co-morbidities. In conclusion, urinary concentration of 11dhTxB2 was a strong independent risk factor for all-cause mortality among patients with stable CAD on aspirin therapy and may be a marker for patients with CAD who require more intensive secondary prevention measures.

UR - http://www.scopus.com/inward/record.url?scp=85010976700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010976700&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2016.12.004

DO - 10.1016/j.amjcard.2016.12.004

M3 - Article

C2 - 28139223

AN - SCOPUS:85010976700

VL - 119

SP - 972

EP - 977

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -